To Study the Effect of Ayurvedic Compound in Patient of Tamaka Shwasa (Bronchial Asthma)â??

Phase 2

Conditions: Health Condition 1: PCS-

Registration Number: CTRI/2023/05/052956

Lead Sponsor: ational Institute of Ayurveda, Deemed to be University

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

1.Patients in the age group of 18-60 yrs.

2.Patients with Intermittent, mild-persistent & moderate-persistent asthma according to GINA classification and are not on regular medication for Asthma.

3.Patients having symptoms of Nasal allergies like sneezing, nasal discharge and having raised eosinophil count with or without chest symptoms cough, wheezing.

4.Patients having FEV1 > 60% of predicted value.

5.Patients who have not received any AYUSH intervention in last 15 days for related symptoms.

Exclusion Criteria

1.Patients having Acute exacerbation of asthma.

2.Patients having FEV1 < 60% of predicted value.

3.Diagnosed cases of tuberculosis, pneumonia, COPD and other acute and chronic pulmonary disorders.

4.K/c/o malignancies of the respiratory and other system.

5.Patients who have consumed AYUSH intervention for related complaints in last 15 days.

6.Patients on regular anti allergic medications.

7.Patients on immunotherapy for allergy.

8.Patients with Haemoglobin less than 9 gm/dl.

9.Patients having concomitant systemic illness like uncontrolled Hypertension, Poorly controlled Diabetes Mellitus, Renal failure, Malignancy, Acute or Chronic liver disease.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in Peak expiratory flow rate(PEFR)from baseline value at the end of 4 week.Timepoint: 0, 2 Week, 4 Week

Secondary Outcome Measures

Name	Time	Method
ï?¼Changes in Absolute Eosinophil count from baseline values at the end of 4th week. <br/ ><br>ï?¼Changes in Asthma control questionnaire (ACQ) score from baseline value at the end of 4th week. <br/ ><br>ï?¼Changes in Nasal symptom score (if present) from baseline value at the end of 4th week. <br/ ><br>ï?¼Average reduction in night time symptoms from baseline value at the end of 4th week. <br/ ><br>Timepoint: 0,2 Week & 4 Week